We estimate Ipca Laboratories' top-line to grow by 28.6% to Rs. 811cr for 1QFY2014. The OPM is expected to dip by 100bp yoy to end at 20.8%. The adjusted net profit is expected to de-grow by 5.1% yoy, on back of dip in OPM.
We maintain neutral on the stock.
